Research Article
Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy
Table 1
Baseline characteristics of breast cancer and noncancer patients with metabolic syndrome.
| | | Breast cancer patients with metabolic syndrome | Noncancer patients with metabolic syndrome | value |
| | Demographics | | Age (years) | 49 ± 8 | 52 ± 10 | 0.442 | | BMI (kg/m2) | 27.8 ± 3.2 | 27.3 ± 2.6 | 0.674 | | Waist circumference (cm) | 92.6 ± 7.4 | 93.2 ± 8.3 | 0.542 |
| | Cardiovascular risk factors | | Coronary heart disease | 0 | 0 | — | | Hypertension | 9 (20%) | 11 (24%) | 0.342 | | High blood glucose | 13 (29%) | 15 (33%) | 0.573 | | Dyslipidemia | 26 (58%) | 24 (53%) | 0.483 | | Beta-blockers | 2 (4%) | 3 (7%) | 0.231 | | ACE inhibitors | 3 (7%) | 2 (4%) | 0.323 |
| | Vital sign | | Systolic blood pressure (mmHg) | 122 ± 18 | 125 ± 15 | 0.673 | | Diastolic blood pressure (mmHg) | 78 ± 10 | 76 ± 11 | 0.523 |
| | Cholesterol level (mmol/L) | | Total cholesterol | 4.88 ± 0.97 | 5.02 ± 1.14 | 0.734 | | LDL-c | 3.11 ± 0.79 | 3.15 ± 0.98 | 0.634 | | TG | 1.82 ± 1.00 | 1.79 ± 1.15 | 0.667 | | Fasting glucose (mmol/L) | 5.40 ± 0.97 | 5.56 ± 1.03 | 0.782 |
| | Breast cancer side | | Left | 22 (49%) | — | — | | Right | 22 (49%) | — | — | | Both | 1 (2%) | — | — |
| | Comprehensive therapy | | Chemotherapy | 45 (100%) | — | — | | Anthracycline use | 31 (69%) | — | — | | Trastuzumab use | 20 (44%) | — | — | | Both of anthracycline and trastuzumab | 11 (24%) | — | — | | Left-side radiotherapy | 16 (36%) | — | — |
|
|
Values as mean ± SD, or n (%). LDL-c: low density lipoprotein cholesterol; TG: triglyceride.
|
